Latest / The Well-Built Life / Cancer Resilience: Surviving Cells and Future Treatments
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:06Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:13Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:17Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:22Speaker 1: and let's dive in. So, let's dive into the fascinating
- 0:25Speaker 1: and complex world of cancer treatments. starting with the early 1960s.
- 0:30Speaker 1: It all began with some groundbreaking research that started to
- 0:35Speaker 1: unveil the survival mechanisms of cancer cells, particularly in leukemia.
- 0:40Speaker 1: What does this really mean, Thomas?
- 0:41Speaker 2: Well, Rachel, imagine cancer cells like a sneaky spy. They
- 0:46Speaker 2: have all sorts of tricks up their sleeves to avoid
- 0:48Speaker 2: being caught by our traditional treatments. The research in the
- 0:51Speaker 2: 60s was like finally pinning these tricks down. Scientists identified
- 0:56Speaker 2: specific ways cancer cells could stay alive and even thrive
- 1:00Speaker 2: even after treatment. How did this change the game?
- 1:03Speaker 1: Exactly. And that's the crucial nuance here. This early work
- 1:07Speaker 1: set a foundational rulebook for how we should tackle cancer.
- 1:11Speaker 1: It highlighted that targeting just one mechanism wouldn't work because
- 1:14Speaker 1: cancer cells engage multiple survival pathways. That's why today, we
- 1:19Speaker 1: see the importance of multi-targeted interventions. Right?
- 1:22Speaker 2: Right on target, Rachel. Think of it like trying to
- 1:25Speaker 2: defeat a complex fortress. You can't just target the walls.
- 1:29Speaker 2: You need to hit every possible entrance and escape route.
- 1:33Speaker 2: In practice, this means combining multiple therapies, chemotherapy, radiation, and
- 1:38Speaker 2: maybe even surgery instead of relying on a single approach.
- 1:42Speaker 2: But even with these layered strategies, to rise a big
- 1:46Speaker 2: challenge we face.
- 1:47Speaker 1: That's where the persistence of cancer cells post-treatment comes in.
- 1:52Speaker 1: As we learn in the research, Conventional treatments like chemotherapy
- 1:56Speaker 1: and radiation are great at targeting fast-dividing cells, but they
- 2:01Speaker 1: often miss out on the dormant stem cells. These cells
- 2:04Speaker 1: can remain dormant for a long time, then burst back
- 2:08Speaker 1: into activity, leading to relapse.
- 2:10Speaker 2: And that's a hard nut to crack. It's like having
- 2:13Speaker 2: a single soldier trying to deal with an army that
- 2:15Speaker 2: can always regroup. These residual stem cells can proliferate more
- 2:20Speaker 2: aggressively once treatment is stopped. which explains why so many
- 2:24Speaker 2: patients see a recurrence. The current guidelines, those 1960 rule books,
- 2:29Speaker 2: if you will, remind us that we can't rely on
- 2:32Speaker 2: just one intervention.
- 2:33Speaker 1: That's why the current understanding of cancer treatment is so nuanced.
- 2:37Speaker 1: It's not a one-size-fits-all solution. It involves a careful balance
- 2:42Speaker 1: of conventional treatments and newer, more integrative approaches. Think of
- 2:47Speaker 1: it like a multi-layered defense system, where each step must
- 2:50Speaker 1: complement the others. It's about targeting not just the cancer,
- 2:55Speaker 1: but also enhancing the immune system's ability to fight it off.
- 2:58Speaker 2: Exactly. A bit like playing whack-a-mole, only in real time.
- 3:03Speaker 2: The goal is to hit all the survival mechanisms at
- 3:06Speaker 2: once and keep a close eye on those lurking stem cells.
- 3:10Speaker 2: It's complex, but ultimately, it means giving patients the best
- 3:13Speaker 2: chance at sustained remission and hopefully a cure.
- 3:17Speaker 1: Absolutely. And as we move forward, the future of cancer
- 3:21Speaker 1: treatment is looking even more promising. We are seeing advancements
- 3:26Speaker 1: in genetic sequencing and personalized medicine, tailor-made to each patient's
- 3:32Speaker 1: unique profile. Adding in emerging technologies like gene editing could
- 3:36Speaker 1: potentially attack cancer stem cells directly, offering new hope even
- 3:41Speaker 1: as we face the persistence of cancer cells. Let's dive
- 3:44Speaker 1: into the nitty-gritty of how cancer stem cells survive post-treatment
- 3:49Speaker 1: and the challenges that come with combating them. Thomas, how
- 3:53Speaker 1: do these dormant cells manage to avoid getting wiped out
- 3:57Speaker 1: by chemotherapy?
- 3:58Speaker 2: Great question, Rachel. Cancer stem cells tend to survive via
- 4:02Speaker 2: multiple survival pathways, which can include resistance to conventional drugs,
- 4:07Speaker 2: the ability to enter a quiescent state, and even recruiting
- 4:10Speaker 2: signals from the tumor microenvironment to protect themselves. It's like
- 4:15Speaker 2: they have a suite of tricks up their sleeves.
- 4:17Speaker 1: Exactly. And these tricks don't just help them survive. They
- 4:21Speaker 1: also make them harder to target. For instance, some cancer
- 4:25Speaker 1: stem cells can pump chemotherapy back out of the cell,
- 4:28Speaker 1: which is a big issue for treatments that rely solely
- 4:31Speaker 1: on chemical agents.
- 4:32Speaker 2: That's a crucial point. Take a step back and think
- 4:36Speaker 2: about it like this. If a cell can expel the
- 4:38Speaker 2: medication before it can do any harm, that's effectively a
- 4:42Speaker 2: form of chemersistance. This is why doctors often combine different drugs,
- 4:47Speaker 2: trying to overcome this pump mechanism.
- 4:49Speaker 1: Right. And that's not the only way they resist. Some
- 4:53Speaker 1: stem cells can also enter a state where they are
- 4:55Speaker 1: not actively dividing. This is called a quiescent state. It's
- 4:59Speaker 1: like they are in hiding and can stay that way
- 5:01Speaker 1: until the coast is clear.
- 5:02Speaker 2: Exactly. Which brings up an interesting contradiction. While these cells
- 5:07Speaker 2: are hard to kill, they are also harder to detect
- 5:09Speaker 2: using current imaging and diagnostic methods. That makes it tricky
- 5:13Speaker 2: to know if the treatment is working and if any
- 5:15Speaker 2: lurking stem cells are still around.
- 5:17Speaker 1: That's wild when you look at the raw numbers. Studies
- 5:20Speaker 1: have shown that even after aggressive chemotherapy, up to 10%
- 5:25Speaker 1: of cancer stem cells can survive and eventually repopulate the tumor.
- 5:30Speaker 1: This is the biggest hurdle in achieving complete remission and
- 5:33Speaker 1: why some cancers keep coming back.
- 5:35Speaker 2: And speaking of hurdles, let's talk about who these challenges
- 5:38Speaker 2: play out for. Scientists and researchers are constantly developing new therapies,
- 5:44Speaker 2: but regulatory bodies have to weigh efficacy against side effects
- 5:47Speaker 2: and cost. It's a delicate balance.
- 5:50Speaker 1: Absolutely. Take the case of gene editing tools. They offer
- 5:54Speaker 1: the promise of directly attacking the survival mechanisms of cancer
- 5:57Speaker 1: stem cells. But we need to consider the practicalities and
- 6:01Speaker 1: ethics involved in using such powerful tools.
- 6:04Speaker 2: That's got to be a tough sell. especially as more
- 6:07Speaker 2: people become aware of the potential risks and benefits. On
- 6:10Speaker 2: the other hand, personal health practitioners and patients themselves have
- 6:15Speaker 2: growing interest in integrative approaches that include diet, exercise, and
- 6:19Speaker 2: natural remedies.
- 6:20Speaker 1: Right, and these are definitely complementary rather than alternative. Integrating
- 6:24Speaker 1: these lifestyle changes with standard treatments could help improve outcomes.
- 6:29Speaker 1: For instance, fasting might reduce iron levels in tumors, making
- 6:33Speaker 1: them more vulnerable to drugs. but we need more research
- 6:36Speaker 1: to back this up. Exactly.
- 6:38Speaker 2: It's all about finding a balance. While traditional treatments aim
- 6:41Speaker 2: to maximize the killing of cancer cells, alternative methods focus
- 6:46Speaker 2: on optimizing the patient's overall health and resilience. It's a
- 6:50Speaker 2: dynamic interplay that we are still working out.
- 6:52Speaker 1: And as we move forward, one thing is clear, the
- 6:55Speaker 1: future lies in personalized and multi-targeted approaches. We need to
- 7:00Speaker 1: understand each patient's unique biology better and tailor treatments accordingly.
- 7:06Speaker 1: It's a complex path, but one full of hope. Now,
- 7:09Speaker 1: let's talk about the latent contradictions in our current approach
- 7:13Speaker 1: to cancer treatment. We often find ourselves stuck between single-mechanism
- 7:17Speaker 1: approaches and the promise of more comprehensive, multi-targeted interventions. How
- 7:23Speaker 1: can we reconcile these approaches?
- 7:25Speaker 2: Thomas. It's a conundrum, Rachel. Single-mechanism treatments like chemotherapy focus
- 7:31Speaker 2: heavily on killing quickly dividing cells, but they don't address
- 7:35Speaker 2: the dormancy and survival mechanisms of cancer stem cells. Meanwhile,
- 7:40Speaker 2: multi-targeted approaches aim to hit every potential pathway, but they
- 7:45Speaker 2: can be complex to administer and manage.
- 7:48Speaker 1: Exactly, and this raises a critical question. Are early detection
- 7:52Speaker 1: screenings really as effective as we'd like them to be?
- 7:55Speaker 1: Some studies suggest they only offer marginal lifespan benefits. How
- 8:00Speaker 1: can we improve the efficacy of these screenings without overhauling
- 8:03Speaker 1: the entire system?
- 8:04Speaker 2: That's a good point. Let's take a look at the data.
- 8:07Speaker 2: While sigmoidoscopy does show some significant life, extension benefits averaging
- 8:13Speaker 2: 110 days, other screening methods, like mammography, don't seem to
- 8:18Speaker 2: have as much impact. This highlights the need for targeted
- 8:22Speaker 2: approaches that actually reduce cancer incidence and mortality.
- 8:26Speaker 1: Right. But it's not just about the screenings. It's also
- 8:29Speaker 1: about the follow-up and lifestyle changes that can make a
- 8:32Speaker 1: big difference. Take, for example, the role of prolonged fasting.
- 8:38Speaker 1: There are studies suggesting it can help trigger the destruction
- 8:41Speaker 1: of cancer stem cells. But how do we implement this
- 8:44Speaker 1: strategy without causing harm to patients?
- 8:47Speaker 2: Great question. The challenge lies in finding the right balance.
- 8:52Speaker 2: Prolonged fasting might be beneficial, but it's not a one-size-fits-all solution.
- 8:57Speaker 2: We need to consider each patient's pre-existing conditions and nutritional needs.
- 9:02Speaker 2: For instance, fasting might work well for someone with a
- 9:06Speaker 2: robust metabolic system, but could be dangerous for someone who
- 9:09Speaker 2: is already frail.
- 9:11Speaker 1: Exactly. This brings us to the debate between institutional and
- 9:14Speaker 1: personalized medicine. On one hand, we have standardized treatment protocols
- 9:19Speaker 1: that are well-established and regulated. On the other, we have
- 9:23Speaker 1: personalized approaches that aim to tailor treatments to individual patient profiles,
- 9:29Speaker 1: considering all potential survival mechanisms.
- 9:31Speaker 2: It's a tricky debate. Institutional approaches offer consistency and wide-ranging applicability,
- 9:38Speaker 2: but they might not address the unique challenges of each patient.
- 9:42Speaker 2: Personalized medicine, by contrast. aims to hit all the right
- 9:45Speaker 2: targets but comes with a higher implementation cost and complexity.
- 9:49Speaker 1: And this complexity can lead to interesting outcomes. For example,
- 9:53Speaker 1: if we rely too heavily on conventional treatments, we might
- 9:57Speaker 1: miss the subtle, multifaceted challenges posed by cancer stem cells.
- 10:02Speaker 1: But if we go too far into personalized treatments, we
- 10:05Speaker 1: might fragment the medical system, making it difficult to scale.
- 10:10Speaker 2: Right. We need to find a middle ground. Maybe it's
- 10:13Speaker 2: about blending the best of both worlds. For instance, using
- 10:17Speaker 2: genetic sequencing to understand specific survival mechanisms and then tailoring
- 10:22Speaker 2: treatments accordingly. This way, we are not just guessing but
- 10:26Speaker 2: actually hitting all the right targets.
- 10:28Speaker 1: Exactly. And as we move forward, we must continue to
- 10:31Speaker 1: integrate new technologies like gene editing, which could provide more
- 10:36Speaker 1: direct targeted interventions. But let's not forget the power of
- 10:39Speaker 1: lifestyle changes and natural remedies too. They can complement conventional
- 10:44Speaker 1: treatments and help build a stronger overall defense against cancer.
- 10:48Speaker 2: Absolutely. It's a collaborative approach that takes into account all
- 10:52Speaker 2: the different factors. Only by embracing this integration can we
- 10:56Speaker 2: truly provide effective patient-centered care.
- 10:59Speaker 1: So, let's dive into some key quotes and unresolved questions
- 11:02Speaker 1: in cancer treatment. One of the most challenging areas is
- 11:06Speaker 1: the future of personalized medicine, genetic sequencing, and the integration
- 11:11Speaker 1: of new technologies like gene editing. How do you think
- 11:15Speaker 1: these advancements can transform our approach? Thomas.
- 11:18Speaker 2: It's fascinating. A quote from Dr. Emily White really captured
- 11:22Speaker 2: the essence. Cancer is not one disease. It's many, many
- 11:27Speaker 2: different diseases in this particular tumor. This speaks to the
- 11:31Speaker 2: need for a more nuanced, personalized treatment strategy. And with
- 11:35Speaker 2: advancements like genetic sequencing, we can finally start to understand
- 11:39Speaker 2: the unique complexities of each tumor.
- 11:41Speaker 1: Exactly. This quote highlights the shift from a one-size-fits-all approach
- 11:46Speaker 1: to a personalized one. Moving forward, we need to leverage
- 11:51Speaker 1: genetic sequencing to identify specific mutations and targeting those mutations directly.
- 11:57Speaker 1: Gene editing tools like CRISPR could play a crucial role.
- 12:01Speaker 1: For instance, imagine being able to selectively remove or deactivate
- 12:06Speaker 1: the genes that allow cancer stem cells to survive. That's
- 12:10Speaker 1: a game-changer.
- 12:11Speaker 2: Absolutely. Another quote that jumps out is from Dr. John Miller,
- 12:15Speaker 2: who says, you'd want to do a multi-targeted approach. So,
- 12:19Speaker 2: in other words, you want to stack the remedies to
- 12:22Speaker 2: hit everything all at once. This means not just hitting
- 12:25Speaker 2: one mechanism, but multiple ones simultaneously to prevent the cancer
- 12:29Speaker 2: from developing resistance. It's like taking multiple antibiotics to prevent
- 12:34Speaker 2: bacterial resistance. Right.
- 12:37Speaker 1: But we must also consider the practicalities. One unresolved question is,
- 12:41Speaker 1: is how to determine the optimal combination of interventions to
- 12:45Speaker 1: achieve maximal efficacy. For example, can we predict which patients
- 12:50Speaker 1: will respond best to gene editing and which might benefit
- 12:54Speaker 1: more from traditional therapies? This combination therapy approach is complex
- 12:59Speaker 1: and requires robust data analysis.
- 13:02Speaker 2: Absolutely. The challenge here is not only figuring out the
- 13:05Speaker 2: right combination, but also ensuring it's feasible and cost-effective. Another
- 13:10Speaker 2: question revolves around identifying subtypes of cancer cells and their
- 13:14Speaker 2: unique survival pathways. It's like finding the vulnerabilities within each tumor,
- 13:19Speaker 2: a piece of the puzzle we are only now beginning
- 13:21Speaker 2: to solve.
- 13:22Speaker 1: Exactly. The future outlook is indeed promising, but we are
- 13:25Speaker 1: still at the mercy of research advancements. On one hand,
- 13:28Speaker 1: we have the potential to significantly enhance treatment outcomes with
- 13:32Speaker 1: personalized and integrative approaches. On the other hand, there is
- 13:36Speaker 1: still much work to be done. The role of lifestyle
- 13:38Speaker 1: changes and natural remedies can be a complementary part of
- 13:42Speaker 1: this journey. For instance, diet, stress reduction, and exercise have
- 13:47Speaker 1: shown potential in supporting overall health and even preventing certain
- 13:52Speaker 1: types of cancer.
- 13:53Speaker 2: True. And let's not overlook the emerging technologies like gene editing.
- 13:57Speaker 2: They can be transformative, especially for treating the dormant cancer
- 14:01Speaker 2: stem cells that often lead to relapse. But we need
- 14:04Speaker 2: to be cautious, too. The technology is still in its
- 14:07Speaker 2: early stages, and we must navigate ethical considerations around its use. Agreed.
- 14:12Speaker 1: The balance between innovation and patient-centered care is critical. As
- 14:16Speaker 1: we move forward, it's essential to stay grounded in practical,
- 14:20Speaker 1: actionable insights. For now, let's focus on integrating these new
- 14:24Speaker 1: tools into our existing treatment protocols to see what works best.
- 14:29Speaker 1: After all, every step we take brings us closer to
- 14:32Speaker 1: a more effective individualized approach. So, let's zoom in on
- 14:37Speaker 1: the future outlook for cancer treatment, specifically focusing on how
- 14:41Speaker 1: advancements in genetic sequencing, personalized medicine, and preventive strategies are
- 14:46Speaker 1: shaping the way we combat this complex disease. Speaking of sequencing, Thomas,
- 14:52Speaker 1: what breakthroughs do you see on the horizon?
- 14:54Speaker 2: Absolutely, Rachel. Genetic sequencing is really where the rubber meets
- 14:59Speaker 2: the road. It's not just about identifying the mutations that
- 15:02Speaker 2: drive cancer. It's about understanding the complete genomic landscape. Take,
- 15:07Speaker 2: for instance, TCGA, the Cancer Genome Atlas. It's helped us
- 15:12Speaker 2: recognize the heterogeneity of tumors, which is critical for personalized treatment.
- 15:17Speaker 2: But wait. But how does that actually play out in practice?
- 15:21Speaker 1: Exactly. Which brings up an interesting contradiction. While sequencing provides
- 15:26Speaker 1: this wealth of information, the challenge lies in translating those
- 15:29Speaker 1: data points into actionable treatments. For example … Knowing that
- 15:33Speaker 1: a certain mutation leads to aggressive cell proliferation isn't the
- 15:37Speaker 1: same as knowing how to target it effectively. How do
- 15:41Speaker 1: we bridge this gap?
- 15:42Speaker 2: That's a great point. Let's look at the role of
- 15:44Speaker 2: CRISPR and other gene editing tools. They offer a precision
- 15:49Speaker 2: that traditional drugs can't match. Say, we can directly target
- 15:54Speaker 2: those dormant stem cells that are often responsible for relapse,
- 15:58Speaker 2: but the ethics around their use are complex. The technology
- 16:02Speaker 2: is still in its early stages, and we must navigate
- 16:05Speaker 2: these ethical considerations carefully.
- 16:08Speaker 1: Right, and that's the crucial nuance here. We are moving
- 16:11Speaker 1: towards a world where every patient's treatment is personalized, but
- 16:15Speaker 1: the challenge is ensuring that these individualized approaches are both
- 16:18Speaker 1: effective and equitable. Speaking of which, preventive strategies are becoming
- 16:24Speaker 1: increasingly important. Lifestyle modifications like diet and exercise have long
- 16:29Speaker 1: been recognized. but they are now backed by more robust evidence.
- 16:33Speaker 1: How do these practical, everyday actions tie into the larger picture?
- 16:38Speaker 2: They are vital, Rachel. Take the example of colorectal cancer.
- 16:42Speaker 2: Studies show that a diet rich in fiber, along with
- 16:45Speaker 2: regular exercise can significantly reduce the risk. This ties into
- 16:50Speaker 2: the broader theme of integrative approaches, combining conventional treatment with
- 16:54Speaker 2: natural and lifestyle-based interventions. It's about creating a comprehensive plan
- 16:59Speaker 2: that works for each individual.
- 17:01Speaker 1: Exactly. And this idea of a holistic integrative approach extends
- 17:05Speaker 1: beyond just diet and exercise. It includes factors like stress
- 17:09Speaker 1: levels and sleep. You mentioned gene editing. CRISPR isn't just
- 17:14Speaker 1: about treatment. It's also about prevention. Say, we could potentially
- 17:19Speaker 1: modify cancer-prone genes before they become cancerous. That's wild when
- 17:23Speaker 1: you look at the raw numbers.
- 17:24Speaker 2: Indeed. But let's not get too optimistic. We still have
- 17:28Speaker 2: a long way to go. The technology is advancing rapidly,
- 17:31Speaker 2: but so are the regulations. Regulatory bodies like the FDA
- 17:35Speaker 2: need to keep up with this pace. They are crucial
- 17:38Speaker 2: in approving these new treatments and ensuring they are safe
- 17:41Speaker 2: and effective.
- 17:42Speaker 1: Agreed. And it's not just about approvals. It's about educating
- 17:45Speaker 1: the public and healthcare providers. People need to understand that
- 17:49Speaker 1: their health is a dynamic, interconnected web of factors. And
- 17:53Speaker 1: healthcare providers, need the tools and resources to deliver these personalized,
- 17:58Speaker 1: integrative treatments effectively.
- 18:00Speaker 2: Absolutely. The future of cancer treatment is looking more promising
- 18:04Speaker 2: than ever, but it's a multidisciplinary effort. From the lab
- 18:08Speaker 2: to the clinic, each stakeholder has a role to play,
- 18:11Speaker 2: and it's this collective effort that will drive us closer
- 18:14Speaker 2: to a more effective, sustainable approach to fighting this disease.
- 18:18Speaker 1: That brings us to the end of today's episode. Thank
- 18:21Speaker 1: you so much for spending part of your day with me.
- 18:24Speaker 1: If you found this episode's tips helpful and want to
- 18:26Speaker 1: make sure you don't miss the next conversation, please take
- 18:30Speaker 1: a quick second to hit that subscribe or follow button
- 18:33Speaker 1: on whatever platform you are listening on. It's a completely
- 18:36Speaker 1: free way to support the show and helps more people
- 18:39Speaker 1: find us. This podcast is independently produced, so if you
- 18:43Speaker 1: are ever in a position where you would like to
- 18:45Speaker 1: help keep it running, we do accept small donations. You
- 18:50Speaker 1: can find a link right in the episode description below.
- 18:53Speaker 1: to buy us a coffee, or contribute what you can.
- 18:56Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 19:01Speaker 1: and we will talk again soon.